BioXcel Therapeutics Receives FDA Fast-Track Designation for BXCL701
Shares of BioXcel Therapeutics surged over 20% in premarket trading after the company announced that its BXCL701 drug candidate...
Revolutionize Your Finance News Experience with MorningExpert!
🌟 Custom-Tailored News Just for You: Say goodbye to information overload. Our cutting-edge filtering technology curates your feed to perfection, delivering only the finance news that matches your interests and professional ambitions.
🔔 Flexible Updates, Your Way: How do you like your updates? Choose from instant app notifications, email digests, or captivating video summaries to stay informed on your own terms.
🎥 Engaging Video Summaries: Pressed for time? Let our expert anchors brief you with video summaries, giving you the essence of each news piece in minutes.
🚨 Personalized Alerts: Never miss out on what matters most. Set custom alarms for topics you’re passionate about, and be the first in the know.
📹 Create Your Own Video Content: Dive deeper into the topics that intrigue you with personalized videos. Generated on demand, these videos bring your chosen keywords or interests to life.
MorningExpert is more than a news app; it’s a dedicated companion for anyone passionate about finance. Whether you’re a seasoned professional, an avid enthusiast, or simply eager to stay updated with the finance world, our app ensures you’re always ahead of the curve.
With features designed to make staying informed effortless and enjoyable—such as custom alarms and on-demand video content—navigating the finance landscape has never been simpler or more tailored to your needs.
Transform the way you consume finance news. Download MorningExpert now and step into a world of precision-informed finance knowledge. Your next-level finance journey starts here!
acquisition adjusted earnings AI analysts apple artificial intelligence Bitcoin CEO China demand dividend Donald Trump Dow Jones Industrial Average earnings economy extreme event FactSet Federal Reserve fourth quarter growth guidance hamas inflation interest rates investment investors Israel Microsoft net income net profit Nvidia profit revenue revenue growth S&P 500 sales shareholders shares stock stock market stocks tesla third quarter Trump Wall Street
Shares of BioXcel Therapeutics surged over 20% in premarket trading after the company announced that its BXCL701 drug candidate...
Shares of Processa Pharmaceuticals soared after the completion of a safety evaluation for its potential cancer treatment. The stock...
Shares of biotech company Gilead Sciences dropped nearly 10% after the failure of a trial for its cancer treatment...
In a devastating turn of events, Meilin Keen, a 27-year-old studying for the bar exam and preparing to move...
Pfizer and Genmab have received priority review from the FDA to convert the accelerated approval of Tivdak for certain...
Los Angeles-based company NeOnc Technologies has filed for an initial public offering with the Securities and Exchange Commission. The...
Merck, Pfizer, and Astellas Pharma have received FDA approval for using Keytruda and Padcev to treat bladder cancer. The...
Merck's cancer treatment Keytruda, in combination with Eisai's drug Lenvima, failed to meet its primary goals in a late-stage...
Intensity Therapeutics shares have doubled to $9.09 after the company announced positive data from its Phase 2 trial of...
Bristol Myers Squibb has received priority review from the FDA for its application to expand the approval of its...